Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Radicicol: From Hsp90 Inhibition to Translation
2026-08-29
A mechanistic and translational framework for using Radicicol across Hsp90, PDK3, adipogenesis, ovarian carcinoma apoptosis, and sepsis inflammation studies—while preserving assay rigor and biological interpretation.
-
FITC Goat Anti-Mouse IgG: From Signal to Biology
2026-08-28
Learn how the FITC Goat Anti-Mouse IgG (H+L) Antibody converts mouse-primary-antibody binding into interpretable fluorescence, from MAVS pathway studies to assay design. This article connects secondary-antibody chemistry with controls, imaging strategy, and mechanistic confidence.
-
TMEM16F in Kupffer Cells Protects Against Listeria
2026-08-28
This study identifies Kupffer cell TMEM16F as a key determinant of host protection during Listeria monocytogenes infection. By combining cell type-specific knockout mice with plasma-membrane repair, inflammation, and liver-metabolism analyses, the authors show that TMEM16F limits Kupffer cell rupture and prevents secondary hepatic injury.
-
Guanabenz Acetate: From GPCRs to Immune Signaling
2026-08-27
A translational framework for using Guanabenz Acetate to connect α2-adrenergic receptor pharmacology with stress-granule and innate immune research—without confusing a mechanistic hypothesis with an antiviral claim.
-
Sildenafil Citrate for Proteoform-Aware Vascular Research
2026-08-27
Sildenafil Citrate connects cGMP pathway perturbation with practical studies of vascular smooth muscle, ERK signaling, and proteoform-dependent drug interactions. This workflow-focused guide shows how to use the compound in cell assays, tissue models, and native mass spectrometry while controlling solubility, timing, selectivity, and off-target interpretation.
-
Angiotensin I: From Precursor to Translation
2026-08-26
Angiotensin I is more than an inactive intermediate: it is a defined substrate for resolving renin–angiotensin system control, ACE activity, cardiovascular signaling, neuroendocrine responses, and emerging peptide-dependent receptor-binding questions. This thought-leadership guide connects mechanism, assay design, product selection, and translational decision-making.
-
Prion Self-Assembly Tunes Mutagenesis for Adaptation
2026-08-26
The reference study identifies prion-based protein self-assembly as a heritable yet reversible regulator of DNA repair, recombination, and mutagenesis in yeast. By combining functional genomics, cell biology, and massively parallel evolution, it shows how protein-state inheritance can redirect adaptation and accelerate antifungal drug resistance.
-
EZ Cap™ Human PTEN mRNA: Research Guide
2026-08-25
EZ Cap™ Human PTEN mRNA (ψUTP) is an in vitro transcribed mRNA reagent designed for transient human PTEN expression in mammalian research systems. Its Cap 1 structure, pseudouridine triphosphate, and poly(A) tail support translation-focused experiments involving mRNA stability enhancement, PI3K/Akt signaling pathway inhibition, and cancer research.
-
Hydroxytyrosol Workflows for Cardiovascular Research
2026-08-25
Build reproducible cell-based assays around Hydroxytyrosol for oxidative stress modulation, inflammatory profiling, and cholesterol-efflux studies. This workflow distinguishes pure compound testing from olive oil extract comparisons and provides practical starting conditions for optimization.
-
Lanabecestat (AZD3293) BACE1 Research Workflow
2026-08-24
Build a translational Alzheimer’s disease research workflow around Lanabecestat (AZD3293), linking amyloid-beta reduction to synaptic-function readouts rather than relying on a single endpoint. Practical dosing, sample-handling, and troubleshooting guidance helps researchers distinguish useful partial BACE1 inhibition from exposure levels that may disrupt neuronal physiology.
-
Machine Learning Prediction of mRNA Lipid Nanoparticles
2026-08-24
The 2022 Acta Pharmaceutica Sinica B study developed a LightGBM model that predicted the performance of lipid nanoparticle formulations for mRNA vaccines from 325 formulation samples. Its value lies in combining data-driven formulation screening with animal validation and molecular dynamics, showing how computational prioritization can reduce reliance on empirical ionizable-lipid screening.
-
RQ3025: Broad-Spectrum Bivalent mRNA Vaccine Evidence
2026-08-23
Lu et al. evaluated RQ3025, a bivalent mRNA vaccine engineered to incorporate spike mutations associated with SARS-CoV-2 evolution. Across several animal models, the candidate induced broad neutralizing activity, protected vaccinated rats against emerging variants, promoted a Th1-biased response, and showed no detected organ pathology after high-dose administration.
-
Kanamycin Sulfate in RNA and Microbial Workflows
2026-08-22
Kanamycin Sulfate provides selective control during bacterial plasmid workflows, while a recent study shows how ultrafiltration can improve downstream circular RNA purity. This article connects antibiotic selection, template preparation, and RNA purification without treating kanamycin as a substitute for a dedicated RNA separation step.
-
Kaempferol Activates NRF2 in Inflammatory Osteolysis
2026-08-22
A 2026 study identifies NRF2 as a direct molecular target of kaempferol and shows that NRF2/HO-1 activation suppresses oxidative stress, osteoclastogenesis, and inflammatory bone loss. By combining biophysical target validation with genetic and pharmacological inhibition, the work provides a mechanistic framework for studying NRF2 signaling pathway inhibition and activation in inflammatory osteolysis.
-
CRISPRa Reveals Splice-Altering Variants in Fibroblasts
2026-08-21
Terkelsen et al. established an mRNA-delivered CRISPR activation strategy that induces expression of tissue-restricted genes in patient-derived skin fibroblasts. By combining dCas9-VPR activation with short- and long-read RNA analyses, the study provides a practical route for evaluating splice-altering variants that cannot be examined in conventional accessible tissues.